Product Details
| Alternative Name: | ErbB2, HER-2, neu, CD340 |
| |
| Clone: | MGR2 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | CaLu 3 lung carcinoma cell line. |
| |
| UniProt ID: | P04626 |
| |
| Species reactivity: | Human
|
| |
| Specificity: | Recognizes an epitope present in the extracellular domain of c-erbB-2 (HER-2; neu). |
| |
| Applications: | Flow Cytometry, IHC (FS), IP
|
| |
| Application Notes: | Immunoprecipitation: Detects a band of ~185kDa. |
| |
| Purity Detail: | Protein G affinity purified. |
| |
| Formulation: | Liquid. In 150mM sodium chloride, pH 7.4, containing 0.02% sodium azide. |
| |
| Handling: | Do not freeze. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | +4°C |
| |
| Scientific Background: | The epidermal growth factor type II receptor, c-erbB2 (HER-2; neu), is a transmembrane tyrosine kinase receptor known to play an important role in coordinating the complex ErbB signalling network and to be involved in the development of breast cancer. When c-erbB-2 is overexpressed at high levels, ligand-independent activation of the c-erbB-2 receptor results in an increased mitogen-activated protein kinase and PI(3)K cell signalling, leading to increased cell proliferation. Overexpression of c-erbB-2 has been associated with resistance to chemotherapy and poor survival in several human tumors. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas: E. Tamborini, et al.; Neuro. Oncol.
12, 776 (2010),
Abstract;
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab: A. Magnifico, et al.; Clin. Cancer Res.
15, 2010 (2009),
Abstract;
Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination: S.M. Pupa, et al.; Cancer Res.
65, 1071 (2005),
Abstract;
Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides: R. Orlandi, et al.; Eur. J. Immunol.
24, 2868 (1994),
Abstract;
p185 HER2/neu epitope mapping with murine monoclonal antibodies: F. Centis, et al.; Hybridoma
11, 267 (1992),
Abstract;
Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification: E. Tagliabue, et al.; Int. J. Cancer
47, 933 (1991),
Abstract;
